Showing 3761-3770 of 5956 results for "".
- Neurolens, Maker of Contoured Prism Technology, Rebrands as Newtonhttps://modernod.com/news/neurolens-maker-of-contoured-prism-technology-rebrands-as-newton/2484138/Neurolens announced its official rebrand to Newton. Named in honor of Sir Isaac Newton, the company said the rebrand reflects Newton’s broader vision to build on its foundation of innovative lens technology and continue driving outcomes that help pa
- Valitor Presents Preclinical Safety Data on Long-Acting Anti-VEGF VLTR-559 for Wet AMDhttps://modernod.com/news/valitor-presents-preclinical-safety-data-on-long-acting-anti-vegf-vltr-559-for-wet-amd/2484137/Valitor announced new preclinical data on VLTR-559, its long-acting anti-VEGF biologic in development for wet age-related macular degeneration (AMD). The findings were featured in a presentation at the Ophthalmology Futures Retina Forum.
- Ashvattha Therapeutics Reports Positive Phase 2 Results for Potential First-in-Class Treatment for DME and Wet AMDhttps://modernod.com/news/ashvattha-therapeutics-reports-positive-phase-2-results-for-potential-first-in-class-treatment-for-dme-and-wet-amd/2484136/Ashvattha Therapeutics announced positive topline results from its phase 2 study of migaldendranib (MGB) in diabetic macular edema (DME) and wet age-related macular degeneration (AMD) at the Euretina Congress. MGB is
- PulseSight Therapeutics to Present New Data on Iron Dysregulation and Ferroptosis in AMD at Euretina 2025https://modernod.com/news/pulsesight-therapeutics-to-present-new-data-on-iron-dysregulation-and-ferroptosis-in-amd-at-euretina-2025/2484133/PulseSight Therapeutics announced that its Chief Scientific Officer, Thierry Bordet, PhD, will present new clinical and preclinical findings on the role of iron dysregulation and ferroptosis in age-related macular degeneration (AMD) at the 25th Euretina Congre
- European Commission Approves Mynzepli as a Biosimilar to Eyleahttps://modernod.com/news/european-commission-approves-mynzepli-as-a-biosimilar-to-eylea/2484127/The European Commission has granted marketing authorization for Mynzepli (aflibercept), a biosimilar to Eylea, developed by Alvotech in partnership with Advanz Pharma. The centralized authorization applies t
- Prevent Blindness Forms New Diabetes + the Eyes Advisory Committeehttps://modernod.com/news/prevent-blindness-forms-new-diabetes-the-eyes-advisory-committee/2482934/Prevent Blindness has created a new Diabetes + the Eyes Advisory Committee. The volunteer panel will guide national initiatives to raise awareness, expand access to care, and improve early detection of diabetes-related eye diseases.
- Ocular Therapeutix Secures FDA Special Protocol Assessment for NPDR Trial of Axpaxlihttps://modernod.com/news/ocular-therapeutix-secures-fda-special-protocol-assessment-for-npdr-trial-of-axpaxli/2482930/Ocular Therapeutix has received written agreement from the FDA under a Special Protocol Assessment (SPA) for the registrational trial design of Axpaxli (OTX-TKI) for the treatment of nonproliferative diabetic retinopathy (NPDR).
- New Research Highlights Lumenis Dynamic Muscle Stimulation Technology in Managing Lower Lid Laxity and Blinking Qualityhttps://modernod.com/news/new-research-highlights-lumenis-dynamic-muscle-stimulation-technology-in-managing-lower-lid-laxity-and-blinking-quality/2482929/New findings demonstrating Lumenis’s Dynamic Muscle Stimulation technology (DMSt) can effectively address lower lid laxity and improve blinking quality in patients with dry eye disease (DED).[1]. According to Lumenis,
- PolyActiva Initiates US Phase 2b Clinical Trial of PA5108 Biodegradable Ocular Implant for Glaucoma and OHThttps://modernod.com/news/polyactiva-enrolls-first-patient-in-us-phase-2b-clinical-trial-of-its-ocular-micro-implant-for-glaucoma-and-ocular-hypertension/2482925/PolyActiva announced the enrollment of the first US patient in its phase 2b clinical trial evaluating PA5108, a novel intracameral, biodegradable micro implant designed to provide sustained IOP reduction in patients with primary open-angle glaucoma (POAG)
- New Study Links Physical Activity to Slower Glaucoma Progressionhttps://modernod.com/news/new-study-links-physical-activity-to-slower-glaucoma-progression/2482921/A new study has revealed that higher levels of physical activity may significantly slow the progression of visual field loss in individuals with glaucoma. The findings suggest that lifestyle modifications could become an important complement to traditional glaucoma